Thyrocare

Thyrocare Technologies Limited is an Indian diagnostic-services brand headquartered in Navi Mumbai. It operates a centralized laboratory network supported by collection centers, franchise outlets and direct service arrangements, with testing performed through large processing facilities rather than through a conventional hospital-based model. The company began in 1996 when A. Velumani, formerly a scientist at the Bhabha Atomic Research Centre, established a laboratory in Byculla, Mumbai, focused initially on thyroid-related testing. Its original specialization gave the company its name and helped it build expertise in high-volume pathology and preventive screening. The business subsequently moved its principal laboratory and headquarters to Navi Mumbai and expanded through a franchise-based sample-collection model. Under this structure, samples are gathered through a broad external network and transported to centralized facilities for processing. This approach allowed Thyrocare to standardize testing, use laboratory automation and seek economies of scale. The company later broadened its portfolio beyond thyroid diagnostics to include more than 350 tests and packages, as well as approximately 83 preventive-care and wellness profiles offered under the Aarogyam brand. A significant expansion of the business occurred in 2010, when Thyrocare raised private-equity capital from CX Partners and established Nuclear Healthcare Limited. The subsidiary used PET-CT technology for the detection and localization of cancerous cells, extending the group beyond routine pathology into nuclear medicine and oncology-related diagnostics. In 2014, Siemens Healthcare installed its Aptio Automation system at Thyrocare's Mumbai laboratory; the installation was described as the world's largest laboratory automation track at that time. Thyrocare completed an initial public offering in April 2016 and became the second diagnostic company in India to list on both the Bombay Stock Exchange and the National Stock Exchange. The public listing gave the company access to capital markets while reinforcing its identity as a scaled diagnostic network rather than a single local laboratory. By 2021, the network was reported to include 1,122 outlets and collection centers across India and parts of Nepal, Bangladesh and the Middle East. The company became part of the PharmEasy ecosystem in June 2021, when API Holdings, the parent of the Indian e-pharmacy and online-healthcare platform PharmEasy, acquired a 66.1 percent controlling stake. The transaction was notable because it was described as the first acquisition of an Indian listed company by a startup. Thyrocare continued operating as a diagnostic brand within the broader digital-health environment. During the COVID-19 pandemic, the company processed more than 800,000 tests per month at the peak of demand. Its diagnostic-access model relied substantially on direct selling and agency arrangements, with the referenced material attributing 68 percent of business to the DSA model. In 2023, Thyrocare integrated SigTuple's AI100 devices to automate manual microscopy across its network. This development reflected the company's continuing emphasis on centralized scale, automation and technology-enabled laboratory workflows. The brand's current identity therefore combines affordable and accessible testing, preventive-health packages, broad collection coverage and increasingly automated diagnostic operations.

Thyrocare was founded in 1996 by A. Velumani, a former scientist at the Bhabha Atomic Research Centre in Mumbai. Its first laboratory was established in Byculla and concentrated on thyroid testing, a specialization that shaped both the company's name and its initial market identity. The business later moved its principal laboratory to Navi Mumbai, where it developed a centralized processing model supported by a wide network of sample-collection points and franchise outlets. The centralized model became the foundation of Thyrocare's scale. Rather than relying primarily on individual neighborhood laboratories, the company organized the collection and movement of specimens to central facilities for processing. This structure enabled greater standardization and supported high-throughput testing. Over time, the company expanded from thyroid diagnostics into a broader clinical-pathology and preventive-health portfolio. Its offerings came to include more than 350 tests and packages and approximately 83 profiles under the Aarogyam preventive-care and wellness brand. In 2010, Thyrocare raised ₹188 crore from CX Partners in exchange for a 30 percent stake. It also created Nuclear Healthcare Limited, a subsidiary using PET-CT technology to identify and locate cancerous cells. This represented an extension from routine laboratory testing into imaging and nuclear-medicine services. In 2014, Siemens Healthcare installed its Aptio Automation system at the Mumbai laboratory. The installation was characterized as the world's largest laboratory automation track at the time and reinforced the company's technology-led, centralized operating model. Thyrocare went public in April 2016 through an initial public offering. It became the second diagnostic company in India to be listed on both the Bombay Stock Exchange and the National Stock Exchange. The listing marked an important transition from a privately funded laboratory business to a publicly traded diagnostic network. The company expanded its collection and outlet footprint across India and selected overseas markets. By 2021, the reported network comprised 1,122 outlets and collection centers in India, parts of Nepal and Bangladesh, and the Middle East. During the COVID-19 pandemic, Thyrocare processed more than 800,000 tests per month at peak demand. The period also brought regulatory scrutiny: civic bodies in Mumbai, Panvel, Navi Mumbai, Thane and Pune reported concerns about COVID-19 reports, including incomplete patient information, discrepancies and alleged false-positive results. These actions included notices, testing restrictions, proposed registration action and local bans. On 26 June 2021, API Holdings, the parent of PharmEasy, acquired a 66.1 percent controlling stake in Thyrocare. The transaction made Thyrocare part of a larger digital-health and e-pharmacy ecosystem and was described as the first acquisition of an Indian listed company by a startup. In 2023, Thyrocare adopted SigTuple's AI100 devices for automated manual microscopy. This initiative continued the company's long-running focus on laboratory automation and operational scale. Its history is consequently defined by specialization in thyroid testing, expansion into preventive and oncology-related diagnostics, centralized processing, public-market growth, digital-health ownership and increasing use of laboratory technology.

• 2023

  AI-enabled microscopy introduced

  [1]Thyrocareen.wikipedia.org

  Thyrocare integrates SigTuple AI100 devices to automate manual microscopy across its network.

• 2021

  API Holdings acquires control

  [1]Thyrocareen.wikipedia.org

  PharmEasy parent API Holdings acquires a 66.1 percent controlling stake in Thyrocare.

• 2016

  Initial public offering

  [1]Thyrocareen.wikipedia.org

  Thyrocare completes an IPO and becomes the second Indian diagnostic firm listed on both BSE and NSE.

• 2014

  Large-scale laboratory automation installed

  [1]Thyrocareen.wikipedia.org

  Siemens Healthcare installs its Aptio Automation track at Thyrocare's Mumbai laboratory.

• 2010

  First private-equity investment

  [1]Thyrocareen.wikipedia.org

  CX Partners invests ₹188 crore for a 30 percent stake, while Thyrocare establishes Nuclear Healthcare Limited for PET-CT-based cancer imaging.

• 1996

  Thyrocare is established

  [1]Thyrocareen.wikipedia.org

  A. Velumani establishes Thyrocare in Mumbai, initially focusing the laboratory on thyroid testing.

A high-volume, centralized diagnostic and preventive-care network emphasizing broad access, standardized laboratory processing, franchise-based sample collection, automation and health-screening packages.

• Clinical diagnostics · 1996

  Thyroid testing

  Thyroid testing was Thyrocare's original specialization and remains central to the brand's identity. The company began with a laboratory focused on thyroid-related investigations before broadening into general pathology and preventive care.

• Preventive healthcare

  Aarogyam

  Aarogyam is Thyrocare's branded range of preventive-care and wellness profiles. The profiles combine multiple tests into screening-oriented packages intended to support routine health monitoring rather than diagnosis of a single condition.

• Laboratory diagnostics

  Clinical pathology test portfolio

  Thyrocare's broader laboratory portfolio includes more than 350 tests and packages spanning routine pathology, health screening and other diagnostic investigations. Samples are collected through its network and processed through centralized laboratory operations.

• Nuclear medicine and oncology imaging · 2010

  PET-CT services

  Through Nuclear Healthcare Limited, Thyrocare entered PET-CT-based imaging for detecting and locating cancerous cells. This offering extended the group beyond laboratory pathology into specialized imaging and nuclear-medicine diagnostics.

• Infectious-disease diagnostics · 2020

  COVID-19 testing

  During the COVID-19 pandemic, Thyrocare provided COVID-19 testing at substantial scale, reportedly processing more than 800,000 tests per month at the peak. The service also became the subject of multiple local regulatory actions in 2020.

• 2020

  COVID-19 reporting and testing disputes

  Several municipal authorities raised concerns about Thyrocare's COVID-19 testing operations. Reported issues included incomplete or incorrect patient information, alleged false-positive results and discrepancies in a report associated with a patient's death. Actions reportedly included a Mumbai show-cause notice, testing restrictions in Panvel and Pune, a Thane ban and a request in Navi Mumbai to cancel the company's registration.

  Source

Read more

• 2023

  Deploy AI-enabled microscopyProduct launch

  Background

  Thyrocare continued investing in automation to support its distributed collection network and centralized laboratory workflows.

  Action taken

  The company integrated SigTuple's AI100 devices to automate manual microscopy.

  Aftermath

  The initiative added artificial-intelligence-assisted microscopy to the network's laboratory technology stack.

  Source

• 2021

  Join the PharmEasy digital-health ecosystemM&A

  Background

  API Holdings, the parent of PharmEasy, pursued control of a scaled diagnostic network.

  Action taken

  API Holdings acquired a 66.1 percent controlling stake in Thyrocare on 26 June 2021.

  Aftermath

  Thyrocare became part of the PharmEasy group and the transaction was characterized as the first acquisition of an Indian listed company by a startup.

  Ownership stake acquired. 66.1% (26 June 2021)

  Source

• 2016

  Go public through an initial public offeringStrategy

  Background

  After expanding its laboratory network and receiving private-equity backing, Thyrocare pursued access to public capital markets.

  Action taken

  The company completed an IPO and listed on both BSE and NSE.

  Aftermath

  Thyrocare became the second diagnostic firm in India to achieve listings on both exchanges.

  Source

• 2014

  Adopt large-scale laboratory automationOther

  Background

  Thyrocare's centralized, high-volume model required technology capable of handling large numbers of samples.

  Action taken

  Siemens Healthcare installed its Aptio Automation track at the Mumbai laboratory.

  Aftermath

  The installation strengthened automation within the company's central processing operation and was described as the world's largest such track at the time.

  Source

• 2010

  Expand into nuclear medicine through Nuclear HealthcareStrategy

  Background

  Thyrocare sought to extend its diagnostic scope beyond routine laboratory testing and created Nuclear Healthcare Limited.

  Action taken

  The subsidiary adopted PET-CT technology to detect and locate cancerous cells.

  Aftermath

  The move added oncology-related imaging and nuclear-medicine capability to the group's diagnostic activities.

  Source

1. 1Thyrocareen.wikipedia.org